Deborah Cromer

Infectious disease modeller and leader of the Infection Epidemiology and Policy Analytics Group at the @KirbyInstitute.

[Deborah Cromer @DebCro]

New work from @KirbyInstitute shows viral clearance predicts clinical protection after COVID-19 treatment. Super important finding to speed up drug development to protect vulnerable populations. Great working with @ProfStephenKent @markpoliz @Tari_Turner https://t.co/j7AZ4Y338w

[Deborah Cromer @DebCro]

Our latest manuscript aggregates all available data to show that updated COVID vaccines increase antibodies to a future variant by 40% compared to last season's vaccine. Another great @KirbyInstitute collaboration between @IAP_Sydney and @viralvaxlab https://t.co/14GGk3XWmx

[Stephen Kent @ProfStephenKent]

Strong link between early viral load reduction by anti-COVID treatments and clinical efficacy.
Helps rapidly progress better treatments.
Bravo, great work by Khoury, Davenport and team. @IAP_Sydney @TheDohertyInst @KirbyInstitute @viralvaxlab https://t.co/aRj6kWHHEG

[Deborah Cromer @DebCro]

Great news - new evidence shows that the effectiveness of COVID-19 treatments can be determined based on how fast treated subjects can clear the virus. https://t.co/vPukvPn3cN More great work from @IAP_Sydney at @KirbyInstitute

[Deborah Cromer @DebCro]

Get boosted! Our new research in Nature Medicine shows both normal and bivalent boosters increase antibody levels, though variant boosters give on average 60% more antibodies. #COVID19Abs https://t.co/oORo4o68CB @IAP_Sydney @KirbyInstitute @ProfStephenKent

[Nature Medicine @NatureMedicine]

Neutralizing #antibody titers elicited by either ancestral or bivalent #COVID19 #vaccine boosters are predicted to increase protection against severe disease due to #SARSCoV2 variants. @DebCro @IAP_Sydney @KirbyInstitute
https://t.co/n0RLyRxbSE

[Deborah Cromer @DebCro]

Another win for neutralising antibodies! Who would have thought they are also correlated with protection against Severe COVID-19?? (Well maybe @IAP_Sydney would!) #COVID19Abs https://t.co/gjMbOv6avP Great working with @m_steain @sarah_sasson @ProfStephenKent @KirbyInstitute

[Megan Steain @m_steain]

Do you like your covid-19 vaccines to give you a good dose of neutralising antibodies? You should because we've shown they correlate not only with protection from symptomatic but also severe disease! Another great collab with ⁦@DebCro⁩ https://t.co/1BEZACwiYX

[Deborah Cromer @DebCro]

Some data (to complement the range of opinions) on variant boosters in our latest preprint https://t.co/GOJ7Rj78Tb

[Eric Topol @EricTopol]

Why to make of the BA.5 boosters coming soon?
The range of opinions
https://t.co/9pXvgEs554 @LNeergaard @AP @Latimes @US_FDA
https://t.co/QN03vrWJm4 @AliceParkNY @TIME @DrPaulOffit

[Deborah Cromer @DebCro]

Our latest meta-analysis comparing ancestral + variant based boosters. Shows the gain from variant boosters is very dependent on the existing protection in the population. https://t.co/GOJ7Rj78Tb @IAP_Sydney @KirbyInstitute @ProfStephenKent @kanta_subbarao @TheDohertyInst

[Deborah Cromer @DebCro]

Follow up on this seminar - the paper I was discussing on correlates of severe COVID-19 is now up as a preprint here https://t.co/aRHpqLfucq

[CMMID @cmmid_lshtm]

Join us online for the next CMMID seminar on "neutralising antibodies as a correlate for predicting protection from #COVID19 disease".

📆 Thursday 9 June
🕛 11:00 BST
🗣️ Dr @DebCro | @KirbyInstitute
🔗 https://t.co/HEEbd3McEn

[Nature Rev Immunol @NatRevImmunol]

What role do T cells play in vaccine-induced immunity to SARS-CoV-2? Discussed here: https://t.co/y6BKGNKDGB
@sarah_sasson
@DebCro
@TricckyLab
@profstephenkent
@viralvaxlab
@EJohnWherry
#COVID-19 #vaccines #SARSCoV2

[Deborah Cromer @DebCro]

Our latest preprint shows that neutralising antibodies predict protection from severe COVID-19. Great collaborating with @ProfStephenKent @m_steain on this important work from the @KirbyInstitute https://t.co/aRHpqLfucq

[Deborah Cromer @DebCro]

New preprint from our group combining work from multiple studies and showing a threshold for neutralising antibodies protecting from SARS-CoV-2. Great collaborating as always with @ProfStephenKent @m_steain @TricckyLab https://t.co/vlxs7l59xM

[Erica Wood @erica_m_wood]

Commentary in @Nature on our analysis of dosing and timing of antibody therapies for COVID-19
Pre-print at medRxiv https://t.co/6TaCpXL7wY

[Erica Wood @erica_m_wood]

Check out Dr Deborah Cromer's interview with @normanswan on today's @RadioNational Health Report discussing our analysis of antibody treatments for COVID-19
https://t.co/ipS56SYjMU
@KirbyInstitute @markpoliz @AndelLestcourt @NSkoetz @Monash_SPHPM

[Deborah Cromer @DebCro]

@EricTopol @ASPRgov @HHS_ASPR @EricTopol Have you seen our preprint showing that passive abs are most effective when given earlier, and could have been given at much lower doses to achieve 90% of the efficacy? (available online today)
https://t.co/w1rSLIndHC
https://t.co/hLuwgONTDe

[Deborah Cromer @DebCro]

New work from our group showing passive antibodies work best when given early. Very effective as prophylaxis / in early stages - once in hospital they have little to no effect.
Determinants of passive antibody effectiveness in SARS-CoV-2 infection
https://t.co/w1rSLIndHC

[Deborah Cromer @DebCro]

New work from our group showing passive antibodies work best when given early. Very effective as prophylaxis / in early stages - once in hospital they have little to no effect.
Determinants of passive antibody effectiveness in SARS-CoV-2 infection
https://t.co/w1rSLIndHC

[NSW Health @NSWHealth]

NSW COVID-19 update – Sunday 23 January 2022

In the 24-hour reporting period to 8pm last night:

- 95.3% of people aged 16+ have had one dose of a COVID-19 vaccine
- 93.9% of people aged 16+ have had two doses of a COVID-19 vaccine

[Deborah Cromer @DebCro]

@NSWHealth 3